{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-034689","form_type":"8-K","ticker":"RCKT","cik":"0001281895","company_name":"ROCKET PHARMACEUTICALS, INC.","filed_at":"2026-08-27T20:06:27+00:00","discovered_at":"2026-08-27T20:07:09.636264+00:00","generated_at":"2026-08-27T20:07:31.263618+00:00","sec_items":["5.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Rocket Pharma adopts severance program; new CEO/GC/COO employment agreements","bullets":["CEO Gaurav Shah gets $674,856 base salary, 60% target bonus; 15-month severance (non-CIC) and 18-month (CIC).","GC Martin Wilson gets $547,313 base salary, 45% target bonus; 12-month severance, plus 12-month CIC terms.","COO Christopher Stevens amendment: 12-month base salary severance, CIC terms include target bonus and prorated bonus.","New severance program covers all eligible US employees; CEO gets 15/18 months, ELT 12 months, VPs 6/9 months, etc."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-034689","json":"https://secwatch.observer/filing/0001140361-26-034689.json","markdown":"https://secwatch.observer/filing/0001140361-26-034689.md","text":"https://secwatch.observer/filing/0001140361-26-034689.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1281895/000114036126034689/0001140361-26-034689-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1281895/000114036126034689/ef20081170_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-27T20:07:31.263618+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}